

JAMIA HAMDARD
School of Pharmaceutical Education and Research
M. Pharm. I Semester Examination (2023-24)

Subject: Pharmacological and Toxicology Screening Methods-I
 Paper Code: MPL 103T

Date: 13-03-24

Maximum Marks: 75
 Time: Three hours

(Write your Roll No. on the top immediately on receipt of this question paper)

Note: This paper has two Sections; A and B.
 Attempt both the sections.

Section A: Answer all the questions.

Section B: Answer any 4 out of 6 questions

Abbreviations Used:

CO-Course Outcome, PO- Program Outcome, BTL- Bloom Taxonomy Level: BT level 1-Remember; BT level 2-Understand; BT level 3- Apply; BT level 4- Analyze; BT level 5- Evaluate; BT level 6- Create.

SECTION-A

Answer the following in brief (Attempt all questions)

5x3= 15 Marks

Q. No 1	Question	BTL	CO	PO
a)	Define bioassay. What are its various types?	1	3	1
b)	What do you mean by Cut-off Time in Screening of Analgesic drugs?	2	3	1
c)	List all the events in a Mating Cycle in a sequential manner.	2	1	9
d)	Outline two methods for induction of diarrhea in experimental animals.	3	3	4
e)	What is the full form of IAEC, CPCSEA & IRB?	1	2	7

SECTION B

Long type Questions (Attempt any 4 out of 6)

4x15= 60 Marks

	Question	BTL	CO	PO
Q. No 2	Describe at least two commonly used methods for pre-clinical screening of anti-ulcer agents. Write their advantages and disadvantages.	2	3	4
Q. No 3	Enlist four parameters in pre-clinical screening of anti-asthmatics drugs with justification.	3	5	4
Q. No 4	Elaborate the various novel screening methods involved in hepatoprotective screening. Write the parameters employed and justify their use in pre-clinical screening of hepatoprotectives.	4	4	4
Q. No 5	Enlist various methods used in the pre-clinical screening of anti-diabetic agents. Describe the most widely used screening method with its advantages and disadvantages.	3	3	4,9
Q. No 6	Outline various methods for preclinical screening of anti – Alzheimer agents. Explain any one method in detail.	4	3	4
Q. No 7	a) Discuss the applications and advantages of transgenic animal development in pharmaceuticals. b) Mention the genetic models for IDDM and NIDDM.	3	1	1,7,10